CURRICULUM VITAE

Raymond Thertulien, M.D., PhD

Home Mailing Address:                                                       Work Address:

511 Queens Road                                                                    Novant Health Weisiger Cancer Institute

Apt 503 125 Queens Road Suite 600        

Charlotte, NC 28207 Charlotte, NC 28204

Telephone:     646-708-2544 (Mobile)                                  (980) 302-6600

Fax (W):                                                                                 (980) 302-6605

Email:            [email protected] (Personal email)                        [email protected]

PROFESSIONAL HISTORY

Current Appointment:                     System Director, Multiple Myeloma & Plasma Cell Disorders

Novant Health Weisiger Cancer Institute-

Charlotte, NC 04/01/2022

Adjunct Assistant Professor of Medicine

University of North Carolina School of Medicine

12/01/2022

Hospital Affiliations:                        Novant Health Presbyterian Medical Center – Charlotte, NC

Previous appointments:                    Director of Clinical Research

AdventHealth Cancer Services – Hendersonville, NC 2015-2022

Hematologist/Medical Oncologist Asheville Hematology & Oncology

Radiation Therapy Associates of Western North Carolina 21st Century Oncology/Genesis care 2010-2022

                                                            Interim Medical Director

AdventHealth Cancer Services (Formerly Park Ridge Health) 12/2020 – 09/2021

Medical Director

Park Ridge Health Cancer Services – Hendersonville, NC 2015 - 2018

Medical Director & Director of Clinical Research  ClinWorks Cancer Research Center

04/2007-12/2009

Member, Optimum Clinical Care, PLLC

4/2007

Associate Director, Oncology

Boehringer-Ingelheim Pharmaceuticals, Inc. 07/2005-03/2007

Assistant Professor of Medicine

Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 07/2001-06/2005

Registration & Licenses:                  Active:

North Carolina Medical Board – Lic. # 2007-00361

Inactive:

The State of Arkansas Medical Board – Lic. # E-2975

State of Connecticut, Dept. of Public Health – Lic. # 043907 State of Michigan – ID # 4301093450

The University of the State of New York – Lic. # 202007

National Provider Identifier:           127 575 9581

Board Certification:                         Internal Medicine, 08/20/1997 – Re-certification, 2007; Not

Currently Certified.

Medical Oncology, 11/08/2000 – Re-certification, 2010 & 2020 Hematology, 11/07/2001 – Re-certification, 2011 & 2022

EDUCATIONAL BACKGROUND

POSTGRADUATE TRAINING:

Fellowship, Hematology/Oncology             Memorial Sloan-Kettering                  7/1/96-6/30/2001

                                                                     Cancer Center (MSKCC)

Fellow in Medicine                                      Joan & Sanford I. Weill Medical College

                                                                     Cornell University                           7/1/96-6/30/2001

Postdoctoral Research Fellow                      Department of Human Genetics       2//1/98-6/30/2001

                                                                     Sloan-Kettering Institute – MSKCC

Internship & Residency                               New York Presbyterian Hospital        6/21/94-6/30/1996

Internal Medicine                                         Cornell University Medical Center

MEDICAL, GRADUATE, & UNDERGRADUATE EDUCATION

                                                                                                Dates                           Date of

School                                              Degree                                 Attended                    Graduation

University of Rochester                   M.D.                            1986-1994             1994

School of Medicine & Dentistry     

University of Rochester                   Ph.D. Microbiology    1986-1994                1994

School of Medicine & Dentistry      & Immunology

University of Rochester                   M.S. Microbiology     1986-1990             1990

School of Medicine & Dentistry      & Immunology

Brooklyn College, CUNY                B.S. Chemistry           1983-1986             1986

Brooklyn, NY 11210

Harvard University                          N/A                             Summer, 1985             N/A    

Cambridge, MA 02138

New York Medical College             N/A                             Summer, 1984             N/A

Valhalla, NY 10595

New York City Technical College  N/A                             1982-1983             N/A

Brooklyn, NY 11201

EXPERIENCE

Description                                      Institution               Supervisor/Mentor               Dates

Medical Director &                          AdventHealth             Theresa Herbert, MD             2015-2021

Director of Clinical Research          Cancer Services                   CMO

Medical Director &                          ClinWorks Cancer      Rebecca McClain, RN            2015-2021

Director of Clinical Research          Research Center                   President

Associate Director                           Boehringer Ingelheim Andree Amelsberg, MD        2005-2007

Oncology                                          Pharmaceuticals, Inc.           Director

Assistant Professor                           Myeloma Institute      Bart Barlogie, MD, PhD  2001-2005

Of Medicine                                     for Research and Therapy         Director

                                                         University of Arkansas for Medical Sciences

Medical Director &                          Batey Relief Alliance Ulrick Gaillard, JD              1998-Present

VP of the Board                               Non-Profit 501 (c)(3)             

Postdoctoral Research                      Sloan-Kettering          Lucio Luzzatto, MD                       1998-2001

Dept. Human Genetics                     Institute-MSKCC

Medical Genetics                             National Institute        Rick Proia, PhD                1/94-2/94

Research Elective                            of Health

Teaching Assistant                           U of R School of         Susan Felten, PhD              1991-1992

(Histology)                                       Medicine & Dentistry

Teaching Assistant                           U of R School of         Mary Notter, PhD              1989-1990

(Histology)                                       Medicine & Dentistry

MARC Research Fellow                  Brooklyn College       R.H. Gavin                                    1985-1986

                                                                                             H.L. Finston                                 1984-1985

ADDITIONAL WORK EXPERIENCE

Locum Tenens

Institution                                        Department/Service Line         Supervisor                 Dates

Roswell Park Cancer Institute         Leukemia Service                Kelvin Lee, MD          5/4/08-5/11/08

Valdese Hospital Cancer center       General Oncology                   C. MacDonald, MD      6/12/08-8/14/08

Roswell Park Cancer Institute         Leukemia Service                Kelvin Lee, MD          8/17/08-8/24/08

Otsego Memorial Hospital               General Oncology                Marilyn Record           11/12/08-3/31/09

Beaufort County Medical Center     General Oncology                Jenny Crews, MD       3/2/09-6/30/09

Bristol Hospital Cancer Center        General Oncology                   D. Dobrzanski, MD       4/1/09-8/24/09

Cancer Centers of NC- Asheville    General Oncology                Don Jackson, MD       11/2/09-1/4/10

HONORS, AWARDS, & SCHOLARSHIPS

Voted #1 (Top Doctor) Hematologist/Oncologist in the State of NC by a Survey of peers -Business North Carolina, (December 2020)

Clinical Scholars Training Program in Biomedical Research – NIH/ Sloan-Kettering Institute, (1998) American-Italian Cancer Foundation – (1998)

Robert Kates Award - University of Rochester (1994)

Dr. Edwin A. Robinson Award- Rush-Henrietta Rotary Club (1994) National Research Service Award - NIGMS (1991)

Outstanding College Students of America Inductee (March, 1988) Dean's Fellowship - University of Rochester (1986)

EFN Scholarship - University of Rochester (1986) Honorary J.E. Salk Scholarship - CUNY (May, 1986)

Joseph Waldstreicher Memorial Award - Brooklyn College (1986) The Graduate Scholarship in Sciences - Brooklyn College (1986) Dean's List - Brooklyn College (1984-86)

MARC Fellow (1984-1986)

Martin Sartner Award - Brooklyn college (February, 1984) Certificate in Recognition of Excellence in Scholarship and Dean's Honor List - Brooklyn College (1983-84)

Araten DJ, Notaro R, Thaler HT, Kernan N, Boulad F, Castro-Malaspina H, Small T, Scaradavou A, Magnan H,  Prockop S, Chaffee S, Gonsky J, Thertulien R, Tarquini R, Luzzatto L. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of 9 patients and a review of the literature.

Haematologica. 2012 Mar;97(3):344-52. Epub 2011 Dec 1.

Ojha RP, Thertulien R. Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data. Ann Oncol. 2012 Feb;23(2):542-3. Epub 2011 Nov 18.

Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP. Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2012 Feb;69(2):341-50. Epub 2011 Jul 8.

Ojha RP, Evans EL, Felini MJ, Singh KP, and Thertulien R. The association between renal cell carcinoma and multiple myeloma: insights from population-based data. BJU Int. 2011 Sep;108(6):825-30. Epub ahead of print 2010 Nov 23.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug;6(8):1418-25.

Ojha RP, Felini MJ, Singh KP, Faramawi MF, and Thertulien R. Radiation therapy for localized or locally advanced prostate adenocarcinoma and myeloma incidence in a population-based cohort. BJU Int. 2011 Mar;107(5):693-7. Epub ahead of print 2010  Dec.

Ojha RP, Brown LM, Felini MJ, Singh KP, Thertulien R. Addressing uncertainty regarding the utility of carbohydrateantigen-125 as a prognostic marker in non-Hodgkin lymphoma. Leuk Lymphoma. 2010 Sep;51(9):1754-7.

Ojha RP, Fishbach LA, Zhou Y, Felini MJ, Singh KP, Thertulien R. Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiol. 2010 Jun;34(3):274-8. Epub 2010 Apr 27.

Ojha RP, Thertulien R, Fischbach LA. Prostate-cancer screening. N Engl J Med. 2009 Jul 9;361(2):203.

Ojha RP, Thertulien R, Fischbach LA. Racial under-representation in clinical trials: Consequence, myth, and proposition. Epidemiol Focus 2008;1(1):4-6.

Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J and Sawyer J. Cytogenetically defined myelodysplasia after melphalan based autotransplants for multiple myeloma linked to poor hematopoietic stem cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2008 Jan 1;111(1):94-100. Epub 2007 Sep 25.

Ojha RP, Prabhakar D, Evans E, Lowery K, Thertulien R, Fischbach LA. RE: Abou-Jawde et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma (Haematologica 2006; 91: 1410-1413). Haematologica. 2007 Apr;92(4):e46.

Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006, 37(9):857-864.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006, 354(10):1021-1030.

Lee CK, Zangari M, Fassas A, Thertulien R, Talamo G, Badros A, Cottler-Fox M, van Rhee F, Barlogie B,  Tricot G. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant. 2006, 37(5):511-515.

Ojha, RP and Thertulien, R. Health Care Policy Issues as a Result of the Genetic Revolution: Implications for Public Health. Am J Public Health. 2005, 95(3): 385-388.

Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep;126(5):715-21.

Miceli M, Atoui R, Thertulien R, Barlogie B, Anaissie E, Walker R, Jones-Jackson L. Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. J Clin Oncol. 2004 Apr 15;22(8):1529-31.

Lee CK, Zangari M, Barlogie B, Fassas A, Van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high- dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004 Apr;33(8):823-8.

Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov;123(3):484-9.

Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Talamo G, Lee CK, and Tricot

G. Thalidomide and Deep Vein Thrombosis In Multiple Myeloma: Risk Factors and Effect on Survival.

Clinical Lymphoma 2003;4(1): 32-35

Lee CK, Barlogie B, Morris C, van Rhee F, Cottler-Fox M, Zangari ME, Fassas A, Anaissie EJ, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Prognostic factors in non-myeloablative allogeneic transplantation for patients with high-risk multiple myeloma. Experimental Hematology 2003; 31:73-80.

Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.Bone Marrow Transplant. 2002 Dec;30(12):873-8.

Karadimitris, A., Li, K., Notaro, R, Araten, D.J., Nafa, K., Thertulien, R., Ladanyi, M., Stevens, A.E., Rosenfeld, C.S., Roberts, I.A.G., Luzzatto, L. Association of T-LGL leukemia and PNH: Further evidence for a pathogenetic link between T cells, Aplastic Anemia, and PNH. Brit J Hematol. 115, 1010-1014, 2001 .

Thertulien, R., Haidaris, P.J., Haidaris, C.G. Intracellular localization of a Trypanosoma cruzi kDNA minicircle transcript using RNA:RNA in situ hybridization. J. Euk. Microbiol. 41(4) 402-407, 1994.

Thertulien, R., Harth, G., Haidaris, C.G. Evidence that the entire length of a kinetoplast DNA minicircle is transcribed in Trypanosoma cruzi. Molecular Microbiology 5(1), 207-215, 1991.

David J Araten, Rosario Notaro, Nancy A Kernan, Farid Boulad, Hugo Castro-Malaspina, Trudy N Small, Andromachi Scaradavou, Heather Magnan, Susan E Prockop, Sara Chaffee, Jason Gonsky, Raymond Thertulien, Roberto Tarquini, and Lucio Luzzatto. Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH). Abstract (#4239) Blood 116 (21):1721, 2010.

Raymond Thertulien, Arthur Frankel, Andrew M. Evens, Jonathan Kaufman, Stephen Horwitz, Albert Assad, Pina M. Cardarelli, Jason Tian, Zuoshun Zhang, Marion MacDowall. A Phase I, Open-Label, Dose- Escalation, Multidose Study of MDX-1401 (Defucosylated Human antiCD30 Monoclonal Antibody) in Patients with CD30-Positive Refractory/Relapsed Hodgkin’s Lymphoma; Abstract #1127 AACR, April 2009.

Rohit P Ojha, Raymond Thertulien, Yi Zhou, and Lori A Fischbach. Prostate cancer treatment and risk of acute myeloid leukemia in a population-based prospective cohort. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5073).

Rohit P Ojha, Raymond Thertulien, Deepak Prabhakar, Yi Zhou, and Lori A Fischbach. A Comparative Investigation of Therapeutic Approaches for Primary Prostate Cancer and Risk of Acute Myeloid Leukemia. Abstract (#1816) Blood 110 (11):538a, 2007.

1. 16. Ojha, Y. Zhou, L.A. Fischbach, M.M. Phillips and R. Thertulien. An Ecologic Perspective of Multiple Myeloma Incidence: Heterogeneous Effects of Industrial Exposures and Socioeconomic Status. Annals of Epidemiology 2007; 17(9):730.

Rohit P. Ojha, Martha M. Phillips, and Raymond Thertulien. Population-Based Risk Assessment for Multiple Myeloma: A Novel Approach for Identifying Potential Environmental Associations. Blood 106(11): 5058, 2006.

Vaishali R. Doshi and Raymond Thertulien. Copper Deficiency Secondary to Bariatric Surgery Mimicking Myelodysplasia. Blood 106: 4930, 2005.

Raymond Thertulien, Bart Barlogie, Maurizio Zangari, Athanasios Fassas, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, Choon-Kee Lee, Klaus Hollmig, Giampaolo Talamo, Guido Tricot . Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T. Abstract (#934) Blood, 104 (11), 2004.

Raymond Thertulien, Bart Barlogie, Jeffrey Sawyer, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, Maurizio Zangari, Guido Tricot. Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2). Abstract (#940) Blood, 104 (11), 2004.

Fenghuang Zhan, Sisi Kapp, Y. Huang, Elias J. Anassie, H. Xu, I. Hanamura, Jeffrey Sawyer, M. Santra, Choon- Kee Lee, Athanasios Fassas, Frits van Rhee, Klaus Hollmig, Giampaulo Talamo, Raymond Thertulien, Guido Tricot, William Barlow, Erik Rasmussen, John Crowley, Bart Barlogie, John Shaughnessy . Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma. Abstract (#784) Blood, 104 (11), 2004.

Maurizio Zangari, Bart Barlogie, Klaus Hollmig, Athanasios Fassas, Erik Rasmussen, Raymond Thertulien, Giampaolo Talamo, Choon-Kee Lee, Guido Tricot . Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM). Abstract (#1480) Blood, 104 (11), 2004.

Klaus Hollmig, Julie Stover, Giampalamo Talamo, Maurizio Zangari, Raymond Thertulien, Frits van Rhee, Athanasios Fassas, Elias Anaissie, Guido Tricot, Bart Barlogie . Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM). Abstract (#929) Blood, 104 (11), 2004.

Athanasios Fassas, Bart Barlogie, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, Giampaolo Talamo, Choon-Kee Lee, Raymond Thertulien, John Crowley, Guido Tricot . Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2). Abstract (#932) Blood, 104 (11), 2004.

Elias J. Anaissie, Marisa H. Miceli, Li Dong, Monica L. Grazziutti, Sabitha Rajan, Giampaolo Talamo, Raymond Thertulien, Anasthasios Fassas, Guido Tricot, Bart Barlogie . Increased Bone Marrow Iron Stores,  Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan – Autologous Stem Cell Transplantation (MEL-ASCT). Abstract (#1158) Blood, 104 (11), 2004.

Elias J. Anaissie, Monica L. Grazziutti, Dong Li, Marisa H. Miceli, Athanasios Fassas, Raymond Thertulien, Sabitha Rajan, Fariba Saghafifar, Guido J. Tricot, Bart Barlogie . The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT). Abstract (#1159) Blood, 104 (11), 2004.

Guido Tricot, John Crowley, Julie Stover, Teresa Milner, Athanasios Fassas, Maurizio Zangari, Raymond Thertulien, Elias Anaissie, Frits van Rhee, Giampalamo Talamo, Klaus Hollmig, Bart Barlogie . Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS). Abstract (#936) Blood, 104 (11), 2004.

Maurizio Zangari, Bart Barlogie, Choon-Kee Lee, Annick E. Tricot, Athanasios Fassas, Elias Anaissie, Klaus Hollmig, Raymond Thertulien, Giampaolo Talamo, Frits van Rhee, Julie M. Stover, Louis Fink, Guido

J. Tricot . Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT). Abstract (#4914) Blood, 104 (11), 2004.

John Shaughnessy, Frank Zhan, Bart Barlogie, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, Maurizio Zangari, Choon-Kee Lee, Giampaolo Talamo, Raymond Thertulien, John Crowley, Guido Tricot . Metaphase Cytogenetic Abnormalities (m-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among 380 Patients with Newly Diagnosed Multiple Myeloma (MM). Abstract (#4935) Blood, 104 (11), 2004.

Raymond Thertulien, Rohit Ojha, Maurizio Zangari, Athanasios Fassas, Elias J. Anaissie, Choon-Kee Lee, Frits vanRhee, Bart Barlogie, Guido J. Tricot. Myelodysplastic CD34+ Clones Can Be Detected by Fluorescent In Situ Hybridization in the Stem Cell Harvest of Myeloma Patients Who Develop Treatment-Related Myelodysplastic Syndrome Following Autologous Transplantation. Abstract (#1540) Blood 102 (11), 2003.

Raymond Thertulien, Joth Jacobson, Jason McCoy, Rohit Ojha, Maurizio Zangari, Athanasios Fassas, Elias Anaissie, Frits Van Rhee, Giampaolo Talamo, Choon-Kee Lee, John Crowley, Guido Tricot, Bart Barlogie. Impact of Cytogenetics of Focal Lesions Biopsied by Fine Needle Aspiration Versus Bone Marrow in Myeloma Patients. Abstract (#2529) Blood, 102 (11), 2003.

Bart Barlogie, Joth Jacobson, Jeffrey Sawyer, John Crowley, Julian A. Terry, Elias Anaissie, Maurizio Zangari,

Raymond Thertulien, Athanasios Fassas, Choon-Kee Lee, Frits Van Rhee, John D. Shaughnessy, Guido

J. Tricot. Increasing CR Frequency as a Strategy toward Extending Event-Free Survival (EFS) and Overall Survival (OS) in Multiple Myeloma (MM): 4-Year Results of Total Therapy II (TT II) Versus Total Therapy I (TT I). Abstract (#136) Blood, 102 (11), 2003.

Maurizio Zangari, Bart Barlogie, Joth Jacobson, Erik Rasmussen, Michael Burns, Bob Kordsmeier, John D. Shaughnessy, Elias J. Anaissie, Raymond Thertulien, Athanasios Fassas, Choon-Kee Lee, David Schenkein, Jerome B. Zeldis, Guido Tricot. VTD Regimen Comprising Velcade (V) + Thalidomide (T) and Added DEX (D) for Non-Responders to V + T Effects a 57% PR Rate among 56 Patients with Myeloma (M) Relapsing after Autologous Transplant. Abstract (#830) Blood 102 (11), 2003.

Maurizio Zangari, Bart Barlogie, Joth Jacobson, Jerome B. Zeldis, Elias J. Anaissie, Raymond Thertulien, Athanasios Fassas, Choon-Kee Lee, John D. Shaughnessy, Guido J. Tricot Revimid 25 mg (REV 25) x 20 Versus 50 mg (REV 50) x 10 q 28 Days with Bridging of 5 mg x 10 Versus 10 mg x 5 as Post-Transplant

Salvage Therapy for Multiple Myeloma (MM). Abstract (#1642) Blood 102 (11), 2003.

Maurizio Zangari, Bart Barlogie, Choon-Kee Lee, Seung-Hee Kang, Athanasios Fassas, Raymond Thertulien, Frits Van Rhee, Giampaolo Talamo, Michael Burns, Elias J. Anaissie, Guido Tricot, Joth Jacobson.

Increment in Bone Phophatase (ALP) in Myeloma Patients during Treatment with Velcade, Thalidomide and Dexamethasome (VTD) Is a Strong Predictor for Response. Abstract (#2544) Blood 102 (11), 2003.

Klaus A. Hollmig, Julie Stover, Joth Jacobson, Jason McCoy, John Crowley, Elias Anaissie, Maurizio Zangari,

Raymond Thertulien, Athanasios Fassas, Choon-Kee Lee, Frits VanRhee, John D. Shaughnessy, Guido

J. Tricot, Bart Barlogie. Cytogenetic Abnormalities at Relapse Influence Overall Survival in Multiple Myeloma Treated on Total Therapy II. Abstract (#1649) Blood 102 (11), 2003.

Elias J. Anaissie, Joth Jacobson, Athanasios B. Fassas, Maurizio Zangari, Raymond Thertulien, Frits VanRhee, Giampaolo Talamo, Guido Tricot, Charles Wendling, Cynthia K. Davis, Klaus Hollmig, Bart Barlogie Safety of Total Therapy II with or without Thalidomide (THAL) for Newly Diagnosed Myeloma: A Study of 475 Consecutive Patients. Abstract (#1657) Blood 102 (11), 2003.

Jason McCoy, Erming Tian, John D. Shaughnessy, Guido Tricot, Jeffrey Sawyer, Maurizio Zangari, Choon-Kee Lee, Athanasios Fassas, Elias Anaissie, Raymond Thertulien, Bart Barlogie. Interphase FISH-Defined Deletion 13 in Total Therapy II (TT II): Adverse Implications with 80% Signal Cut Point - Interpretation in the Context of Cytogenetic Abnormalities (CA) . Abstract (#2512) Blood 102 (11), 2003.

Choon Kee Lee, Bart Barlogie, Seung-Hee Kang, Joshua Epstein, John Shaughnessy, Maurizio Zangari, Athanasios Fassas, Michele H. Cottler-Fox, Frits Van Rhee, Raymond Thertulien, Giampaolo Talamo, Elias J. Anaissie, Guido Tricot. Proliferative, Cytogenetic and Gene Cluster Characteristics of Myeloma Phenotype. Abstract (#1623) Blood 102 (11), 2003.

Choon Kee Lee, Bart Barlogie, Seung-Hee Kang, John Shaughnessy, Maurizio Zangari, Athanasios Fassas, Joshua Epstein, Frits Van Rhee, Raymond Thertulien, Giampaolo Talamo, Michele H. Cottler-Fox, Elias J. Anaissie, Guido Tricot Presence of High (10%) Ki67+ Myeloma Cells Is Associated with CD117- Phenotype, Abnormal Chromosomes and Agressive Myeloma Gene Clusters, and Portends a Poor Outcome after Autotransplant. Abstract (#2527) Blood 102 (11), 2003.

Choon Kee Lee, Bart Barlogie, Seung-Hee Kang, Joshua Epstein, John Shaughnessy, Maurizio Zangari, Athanasios B.-T. Fassas, Michele H. Cottler-Fox, Frits Van Rhee, Raymond Thertulien, Giampaolo Talamo, Elias J. Anaissie, Guido Tricot. CD52+CD117- Myeloma Phenotype Is Associated with High Risk for Relapse in Newly Diagnosed Patients. Abstract (#3485) Blood 102 (11), 2003.

Athanasios B.-T. Fassas, Jeffery Sawyer, Jason McCoy, Elias J. Anaissie, Choon Kee Lee, Giampaolo Talamo, Charles Wendling, Maurizio Zangari, Frits Van Rhee, Raymond Thertulien, Guido J. Tricot, Bart Barlogie. Absence of Hypodiploidy and/or Chromosome 13 Abnormalities (hypo-CA13) Confers Superior Survival in Multiple Myeloma (MM) Patients (pts): Interim Analysis of Total Therapy (TT) II Trial. Abstract (#2534) Blood 102 (11), 2003.

Frank Zhan, Bob Kordsmeier, Raymond Thertulien, Maurizio Zangari, Choon-Kee Lee, Giampaolo Talamo, Athanasios Fassas, Elias J. Anaissie, Frits vanRhee, Guido J. Tricot, Bart Barlogie, John Shaughnessy. Prediction of Two-Year Survival of Patients with Myeloma Treated with Total Therapy II Using a Multivariate Discriminate Model of Gene Expression. Abstract (#3483) Blood 102 (11), 2003.

Tahsine H. Mahfouz, Fariba Saghafifar, Marisa H. Miceli, Laurie B. Jones, Ronald Walker, Raymond Thertulien, Bart Barlogie, Elias J. Anaissie. FDG-PET Has a Significant Impact on the Diagnosis and Management of Infection in Patients with Hematological Cancer: A Study of 73 Infections in 67 Patients. Abstract (#3618) Blood 102 (11), 2003.

Stefano Tarantolo, Patrice Watson, Peter H. Wiernik, Dennis D. Weisenburger, David Hogg, Brigid Quinn- Laquer, Warren G. Sanger, Karin Igsur Bergsagel, Lief Bergsagel, Francois Eisinger, Hagay Sobol, Laetitia Huiart, Helga Ogmundsdottir, O.I. Olopade, Raymond Thertulien, Thea Tlsty, Michael Kuehl, Carlo Croce, Albert de la Chapelle, Kenneth Offit, Henry T. Lynch. Familial Multiple Myeloma (MM) Registry: An International Consortium for MM Family Studies. Abstract (#5233) Blood 102 (11), 2003.

Raymond Thertulien, Bart Barlogie, Elias Anaissie, Athanasios Fassas, Choon-Kee Lee, Frits van Rhee, Maurizio Zangari, Guido Tricot. MEL100-DT PACE Hybrid Regimen for Advanced Multiple Myeloma (MM) Is Safe and Produces High CR Rate Also in the Presence of Cytogenetic Abnormalities (CA) Including CA 13. Abstract (# 1683) Blood 100 (11), 435a, 2002.

Guido J. Tricot, Raymond Thertulien, Joth Jacobson, Athanasios Fassas, Maurizio Zangari, Elias J. Anaissie, Bart Barlogie. Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM). Abstract (# 357) Blood 100 (11), 97a, 2002.

Bart Barlogie, Guido Tricot, Elias Anaissie, Athanasios Fassas, Choon-Kee Lee, Raymond Thertulien, Frits van Rhee, Maurizio Zangari. Long-Term Follow-Up (Median of 4 Yr) of 169 Patients Receiving Thalidomide (THAL) for Advanced and Refractory Multiple Myeloma (MM): Superior Survival in the Absence of Cytogenetic Abnormalities (CA) and Low -2 Microglobulin (B2M). Abstract (# 789) Blood 100 (11), 210a, 2002.

Maurizio Zangari, Bart Barlogie, Jenifer Prather, Paul Eddlemon, Elias Anaissie, Choon-Kee Lee, Guido Tricot, Raymond Thertulien, Frits van Rhee. Marked Activity Also in Del 13 Multiple Myeloma (MM) of PS 341 (PS) and Subsequent Thalidomide (THAL) in a Setting of Resistance to Post-Autotransplant Salvage Therapies. Abstract (# 387) Blood 100 (11), 105a, 2002.

Maurizio Zangari, Bart Barlogie, Elias J. Anaissie, Fariba Saghafifar, Athanasios Fassas, Choon-Kee Lee, Raymond Thertulien, Frits van Rhee, Jerome Zeldis, Louis Fink, Guido Tricot. Abrogation of Thrombogenic Effect of the Doxorubicin (DOX)- Thalidomide (THAL) Combination as Part of Total Therapy II (TTII) for Newley Diagnosed Multiple Myeloma (MM) by Effective Anti-Coagulation with Low Molecular Weight Heparin(LMWH). Abstract (# 1546) Blood 100 (11), 398a, 2002.

Choon Kee Lee, Bart Barlogie, Maurizio Zangari, Athanasios Fassas, Ashraf Z. Badros, Frits van Rhee, Michele

H. Cottler-Fox, Raymond Thertulien, Firas Muwalla, Syed Mazher, Elias J. Anaissie, Guido Tricot. Dialysis-Dependent Renal Failure in Patients with Myeloma Can Be Reversed by High-Dose Myeloablative Therapy and Autotransplant. Abstract (# 1670) Blood 100 (11), 431-2a, 2002.

Choon Kee Lee, Bart Barlogie, Maurizio Zangari, Athanasios Fassas, John Shaughnessy, Frits van Rhee, Michele

H. Cottler-Fox, Raymond Thertulien, Firas Muwalla, Elias J. Anaissie, Guido Tricot. Negative Impact of Chromosome 13 Abnormalities on Further Transplant for Patients with Relapsing Myeloma after Tandem Transplant. Abstract (# 1671) Blood 100 (11), 432a, 2002.

Choon Kee Lee, Bart Barlogie, Maurizio Zangari, Athanasios Fassas, Frits van Rhee, Michele H. Cottler-Fox, Raymond Thertulien, Firas Muwalla, Elias J. Anaissie, Guido Tricot. D.T. PACE, a New Effective Angio-Chemotherapy for Patients with Previously Treated Myeloma. Abstract (# 3231) Blood 100 (11), 818a, 2002.

Choon Kee Lee, Bart Barlogie, Christopher L. Morris, Ashraf Z. Badros, Frits van Rhee, Michele H. Cottler-Fox, Elias J. Anaissie, Maurizio Zangari, Athanasios Fassas, Raymond Thertulien, Firas Muwalla, Guido Tricot. High Rates of Infectious Complications Associated with HLA-Mismatched or Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation after Non-Myeloablative Conditioning for Patients with Multiple Myeloma. . Abstract (# 3388) Blood 100 (11), 859a, 2002.

Ronald Walker, Bart Barlogie, Rajesh Sethi, Edguardo Angtuaco, Elias Anaissie, Athanasios Fassas, Choon-Kee Lee, Raymond Thertulien, Frits van Rhee, Maurizio Zangari, Ernest Ferris, Guido Tricot. Magnetic Resonance Imaging (MRI) as Part of Staging Work-Up for Newly Diagnosed Multiple Myeloma (MM):

• • • 5 Focal Lesions and LDH Elevation Identify Inferior Survival in 402 Patients Receiving Total Therapy II (TT II).Abstract (# 2350) Blood 100 (11), 598a, 2002.

Michele Cottler-Fox, Bart Barlogie, Elias Anaissie, Maurizio Zangari, Athanasios Fassas, Choon-Kee Lee, Frits van Rhee, Raymond Thertulien, Guido Tricot. Determinants of High and Low CD 34 Yield after CAD as Part of Total Therapy II (TT II) for Newly Diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). Abstract (# 5491) Blood 100 (11), 477b, 2002.

Zangari M, Siegel E, Anaissie E, Agha J, Saghafifar F, Thertulien R, Fassas A, Lee CK, Muwalla F, Mazher S, Van Rhee F, Fink L, Barlogie B, Tricot G. Synergistic thrombogenic factors in myeloma patients treated with thalidomide. Abstract (# 1106). American Society of Clinical Oncology proceedings v 21, 277a, 2002.

Thertulien, R., Barlogie, B., Fassas, A., Eddlemon, P., Zangari, M., Muwalla, F., Morris, C., Anaissie, E., Fox, M., Tricot, G. Hybrid Mel/DTPACE Autotransplant Regimen for Multiple Myeloma (MM) – Safety and Efficacy Data in Pilot Study of 15 Patients. Abstract (# 2869) Blood 98 (11), 2001.

Thertulien, R., Michaeli, J., and Luzzatto. L. Isolation of differentially expressed genes in multiple myeloma.

Abstract (#664) Blood 96 (11), 2000.

Karadimitris, A., Li, K., Araten, D.J., Nafa, K., Thertulien, R., Stevens, A.E., Ladanyi, M., Roberts, I.AG., Luzzatto, L. A novel association of T-LGL leukemia and PNH supports the central role of a T-cell- mediated immune response in the pathogenesis of PNH. Abstract (#995) Blood 96 (11), 2000.

Thertulien, R. and Luzzatto. L. Isolation of differentially expressed genes in multiple myeloma. Abstract presented at the SmithKline Beecham National Medical Oncology Fellow’s Forum,  Ponte Vedra Beach, FL. 2000.

Notaro, R., Karadimitris, A., Araten, D., Nafa, K., Thertulien, R., Luzzatto, L. Relative Dynamics of

Telomere Lengths in PNH and Normal Granulocytes from PNH Patients. Abstract (#1776) Blood 94 (10), 1999.

Thertulien, R., Harth, G., Haidaris, C.G. Evidence that the entire length of a kinetoplast DNA minicircle is transcribed in Trypanosoma cruzi. Abstract presented at the Molecular Parasitology Meeting; Marine Biological Laboratories, Woods Hole, MA. 1990

Thertulien, R., Gavin, R.H. Localization and Characterization of Actin from Tetrahymena.  Abstract presented at the 14th Annual Minority Biomedical Research Support Symposium; New Orleans, LA, 1986.

Finston, H.L, Thertulien, R., Kong, B., Pierrot, P. Liquid-Liquid Solvent Extraction. Abstract presented at the 13th Annual Minority Biomedical Research Support symposium; Miami, FL., 1985.

Finston, H.L., Thertulien, R., Kong, B., Pierrot, P. Solvent Extraction at Near Neutral pH.  Abstract presented at the Fourth MARC Scholars Conference; Washington, D.C., 1984.

American society of Hematology (1999-Present) American Society of Clinical Oncology (2000-Present) American Association for Cancer Research (2007-2017) Western Carolina Medical Society – (2010 – 2022)

Board Member – (2013 - 2021) President of the Board – 2018-2019

INTERESTS                                                                       REFERENCES        

Art, Sports, Music, Reading.                                                  Av